

City of Hope Presents

Annual

Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

April 5 to 6, 2025

Waldorf Astoria Las Vegas, NV

cme.cityofhope.org



♦ Table of Contents ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

- **WELCOME**
- GENERAL INFORMATION
 - > Important Reminders
 - **<u>Conference Details: Location, Times, etc.</u>**
- CME INFORMATION
 - > <u>CME Credit Information</u>
 - Instructions for Obtaining CME Credit
 - AMA PRA Category 1 Credit[™]
 - Core Competencies Information Sheet
 - Disclosures
- E-SYLLABUS
- WIFI INFORMATION
- **MEET THE FACULTY RECEPTION**
- **UPCOMING SYMPOSIA**
- CONFERENCE SCHEDULE
- CONFERENCE TASKS
 - Link to Conference Evaluation
- **ACKNOWLEDGMENT OF COMMERCIAL SUPPORT**
 - Sponsorship & Exhibits
 - Sponsorship Ads

🛣 Cityof Hope...

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

Welcome to the Annual Advances and Innovations in Endoscopic Oncology

and Multidisciplinary Gastrointestinal Cancer Care, in Las Vegas, NV!

On behalf of City of Hope and the Department of Continuing Medical Education, we would like to thank you for joining us for this educational activity.

Interest and input from our participants encouraged us to continue to expand the focus of this conference, incorporating requests and suggestions from attendees. The previous years of this conference have been a great success and we are happy to have you join us this year.

Our goal is to provide the desired information and skills which physicians and allied health care providers need in order to better serve their patient populations and research. Your thoughts are valuable and important, so please share them with us on the evaluation that will be emailed to you at the conclusion of the conference.

The links to the *Evaluation* can also be accessed under the **Conference Tasks** page of this handout.

Should you have any questions, please visit the conference staff at the registration desk.

For post-conference CME information, please contact:

City of Hope Department of Continuing Medical Education 1500 E. Duarte Road, Bldg. #175 Duarte, CA 91010 <u>cme@coh.org</u> (626) 218-5622



♦ General Information ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

Contactless Registrant Sign-in:

You must confirm your attendance **daily** at the conference.

You will be provided with a unique code to record your attendance. You will need to text in the attendance code to the City of Hope CME text-in number (626-314-7448). Registrant sign-in, can also be completed via QR Code.

To ensure you are ready for Contactless Registrant Sign-in:

1. Please be sure to have with you the cell phone (mobile) you registered in your CME Profile. If you have not done so yet, confirm your mobile number (you only have to do this once)

Log on to: <u>https://cme.cityofhope.org</u> Once logged on, click on **"My Account"** on the top right corner \rightarrow Click on the "Edit" tab \rightarrow then click on the "Mobile" tab:

- If mobile number is correct and you see the word "DONE!" simply close out the page. You are done!
- If you see "CONFIRM NUMBER", your mobile number is not yet confirmed. To confirm it:
 - 1. Click "DELETE NUMBER AND START OVER."
 - 2. Enter your mobile number (do not include hyphens/dashes), to receive a confirmation code.
 - 3. Enter Confirmation Code (this will be texted to you).
 - 4. Click "CONFIRM NUMBER" and once you see "DONE!" close out the page. You are done!
- 2. Save the City of Hope CME text-in number as a contact in your cell phone: 626-314-7448
- 3. Please ensure your cell phone is fully charged, as charging stations will not be available in the conference area.



♦ General Information ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

MEETING MATERIALS

Check-in at the registration desk to receive conference materials and a name badge.

CONFERENCE NAME BADGE

Official conference name badge *must* be worn at all times to gain and maintain access to conference room and meals.

CONFERENCE LOCATION

EDUCATIONAL SESSIONS

Waldorf Astoria Las Vegas 3752 Las Vegas Blvd S. Las Vegas, NV 89158 Waldorf Ballroom

REGISTRATION DESK - HOURS OF OPERATION

DATE	TIME	LOCATION
Saturday, April 5	7:00 AM – 3:15 PM	Waldorf Ballroom
Sunday, April 6	7:15 AM – 3:25 PM	Waldorf Ballroom

CONFERENCE MEALS & BREAKS

DATE	DESCRIPTION	TIME	LOCATION
Saturday, April 5	Breakfast	7:00 – 7:50 AM	Waldorf Ballroom
Saturday, April 5	Refreshment Break	9:55 – 10:35 AM	Waldorf Ballroom
Saturday, April 5	Lunch	12:15 – 1:45 PM	Waldorf Ballroom
Saturday, April 5	Meet the Faculty Reception	3:45 – 5:45 PM	Waldorf Ballroom
Sunday, April 6	Breakfast	7:15 – 8:15 AM	Waldorf Ballroom
Sunday, April 6	Refreshment Break	9:45 – 10:25 AM	Waldorf Ballroom
Sunday, April 6	Lunch	12:00 – 1:30 PM	Waldorf Ballroom

EXHIBIT HALL & HOURS

DATE	TIME	LOCATION
Saturday, April 5	7:00 – 7:50 AM; 9:55 – 10:35 AM; 12:15 – 1:45 PM	Waldorf Ballroom
Sunday, April 6	7:15 – 8:15 AM; 9:45 – 10:25 AM; 12:00 – 1:30 PM	Waldorf Ballroom



♦ CME Information ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

Accreditation Statement

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

City of Hope designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the educational activity.

The following may apply AMA PRA Category 1 Credit[™] for license renewal:

- **Registered Nurses:** Nurses may report up to 9.75 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
- **Physician Assistants:** The National Commission on Certification of Physician Assistants states that *AMA PRA Category 1 Credit*[™] accredited courses are acceptable for continuing medical education requirements for recertification.



Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for

the purpose of granting ABS credit.

Disclosure

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity. Faculty and Planners have provided written disclosure of all relevant financial relationships which have been included in this handout. Any potential conflicts relative to the disclosure(s) have been resolved. City of Hope further encourages faculty/presenters to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

City of Hope may find it necessary to substitute faculty with comparable expertise on those rare occasions necessitated by illness, unforeseen scheduling conflicts or extraordinary occurrences beyond the control of City of Hope.



♦ CME Information ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

Instructions for Obtaining CME Credit (AMA PRA Category 1 Credit™):

During the conference participants will be provided with a unique attendance code to record their attendance. Physicians and others who wish to receive AMA PRA Category 1 Credit[™] for this activity **must** text in the unique attendance code for this conference, daily, in order to record their attendance.

The unique attendance code will need to be texted to the City of Hope CME text-in number (626-314-7448). If you have not yet saved this number as contact on your cell phone, please do so now, to ensure you are ready to record your attendance. The text-in method will also be facilitated via a QR code that will be available upon check-in, at the conference registration desk.

Credit transcripts will be updated within a week to reflect your participation.

Retrieve your CME Transcripts by visiting the City of Hope CME website: <u>https://cme.cityofhope.org/</u> Log in using your registered email and password.

Quick Tip!

Have trouble remembering your password? Once you log in to your account, do not log out, so you do not have to log back in!

Once logged in, click on the <u>My Transcripts</u> section at the top of the page, and click on "<u>Completed Activities</u>". You can then print your Credit Transcript or the individual Certificate, if desired.

For assistance, contact the Department of Continuing Medical Education at 626-218-5622 or <u>cme@coh.org</u>.

For assistance, contact the Department of Continuing Medical Education at 626-218-5622 or <u>cme@coh.org</u>.



CORE COMPETENCIES INFORMATION SHEET

PRACTICE-BASED LEARNING AND IMPROVEMENT

Physicians must be able to investigate and evaluate their patient care practices, appraise and assimilate scientific evidence, and improve their patient care practices. CME programs address these issues if the topics relate to:

- analyzing practice experience and performing practice-based improvement activities using a systematic methodology
- locating, appraising, and assimilating evidence from scientific studies related to their patients' health problems
- obtaining and using information about their own population of patients and the larger population from which their patients are drawn
- applying knowledge of study designs and statistical methods to the appraisal of clinical studies and other information on diagnostic and therapeutic effectiveness
- using information technology to manage information, access on-line medical information; and support their own education
- facilitating the learning of students and other health care professionals

PATIENT CARE

Physicians must be able to provide patient care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health. **CME programs address these issues if they address topics related to**:

- The ability to communicate effectively and demonstrate caring and respectful behaviors when interacting with patients and their families;
- gathering essential and accurate information about their patients
- making informed decisions about diagnostic and therapeutic interventions based on patient information and preferences, up-to-date scientific evidence, and clinical judgment
- developing and carrying out patient management plans
- counseling and educating patients and their families
- using information technology to support patient care decisions and patient education
- performing competently all medical and invasive procedures considered essential for the area of practice
- providing health care services aimed at preventing health problems or maintaining health
- working with health care professionals, including those from other disciplines, to provide patient-focused care

SYSTEMS-BASED PRACTICE

Physicians must demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value. **CME programs address these issues if the topics relate to:**

- understanding how their patient care and other professional practices affect other health care professionals, the health care organization, and the larger society and how these elements of the system affect their own practice
- knowing how types of medical practice and delivery systems differ from one another, including methods of controlling health care costs and allocating resources
- practicing cost-effective health care and resource allocation that does not compromise quality of care
- advocating for quality patient care and assisting patients in dealing with system complexities
- knowing how to partner with health care managers and health care providers to assess, coordinate, and improve health care and knowing how these activities can affect system performance

MEDICAL KNOWLEDGE

Physicians must demonstrate knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care. **CME programs address these issues if the topics relate to:**

- demonstration of an investigatory and analytic thinking approach to clinical situations
- knowledge and application of the basic and clinically supportive sciences which are appropriate to their discipline

INTERPERSONAL AND COMMUNICATION SKILLS

Physicians must be able to demonstrate interpersonal and communication skills that result in effective information exchange and teaming with patients, their patients families, and professional associates. **CME programs address these issues if the topics relate to:**

- creating and sustaining a therapeutic and ethically sound relationship with patients
- using effective listening skills and eliciting and providing information using effective nonverbal, explanatory, questioning, and writing skills
- working effectively with others as a member or leader of a health care team or other professional group

PROFESSIONALISM

Physicians must demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population. **CME programs address these issues if the topics relate to:**

- demonstrating respect, compassion, and integrity; responsiveness to the needs of patients and society that supersedes self-interest; accountability to patients, society, and the profession; and a commitment to excellence and on-going professional development
- demonstrating a commitment to ethical principles pertaining to provision or withholding of clinical care, confidentiality of patient information, informed consent, and business practices
- demonstrating sensitivity and responsiveness to patients' culture, age, gender, and disabilities



Department of Continuing Medical Education

Conflict of Interest Disclosure and Resolution & Core Competencies Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care April 5 to 6, 2025

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the <u>Standards for Integrity and Independence in Accredited Continuing Education</u> of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term "core competencies" refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Arya Amini, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Michelle A. Anderson, MD, MSc	Consultant for Boston Scientific.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	3 & 4
Sue Damico, AOCNP	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Vicki Doctor, MS, BSN	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Sarah Enslin, PA-C	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 3, 5 & 6
Marwan Fakih, MD	Consultant for AbbVie, Adagene, Bayer, Bristol Myers Squibb, Delcatch, Eisai, Entos, Janssen, Merck, Microbial Machines, Mirati, Nouscom, Pfizer, Roche/Genentech, Summit, Taiho, Tempus, and Totus.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Hannah Farfour, DNP, AGPCNP-BC	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 2, 3, 5 & 6
Emre Gorgun, MD, MBA	Consultant for Boston Scientific, Dilumen, and Intuitive Surgical.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Stephen B. Gruber, MD, PhD	Grant/Research Support from AbbVie, AstraZeneca, Eisai, HaloDx, and Invitae.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 5
Maarouf A. Hoteit, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
lordan lannuzzi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 6
Gregory Idos, MD, MS	Grant/Research Support from Adela.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	3 & 4
Toufic Kachaamy, MD	Consultant for Boston Scientific, Creo Medical, Cook Medical, Exact Sciences, Medtronic, Olympus, Pentax Medical, and Steris; On the Speakers Bureau for Grail; Other financial/material interests (Royalties) in Micro-Tech Endoscopy.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator 1, 2, 3 & 4
Andreas M. Kaiser, MD	Consultant for Intuitive Surgical.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Moderator
Pashtoon Kasi, MD, MS	Consultant for Agenus, Astellas, AstraZeneca, Bayer, BostonGene, Daiichi Sankyo, Eli Lilly, Elicio Therapeutics, Foundation Medicine, Guardant Health, Illumunia, Merck, Natera, Neogenomics, Regeneron, SAGA Diagnostics, SeaGen, Taiho, Tempus, and Xilio; Grant/Research Support from Agenus, Merck, and Novartis.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. Off-label use of liquid biopsies circulating tumor DNA - ctDNA and circulating tumor cells (CTCs).	1, 2, 3 & 4
/ivek Kaul, MD	Consultant for Castle Biosciences, Cook Medical, Exact Sciences, Ironwood Pharma, Provation Medical, and Steris.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator
Sameer Keole, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
onathan Kessler, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3 & 4
Ajaz M. Khan, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Steven H. Lin, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
David Luyimbazi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
/eeral M. Oza, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Rahul Pannala, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Mital Patel, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
N. Jewel Samadder, MD, MS	Consultant for Nouscom and Recursion Pharmaceuticals.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner 1, 2, 3, 4 & 5
Neil R. Sharma, MD	Consultant for Boston Scientific, Medtronic, Olympus, and Steris.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner 1, 2, 4 & 5
Gagandeep Singh, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Michael S. Smith, MD, MBA	Consultant for Steris Endoscopy.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2, 3, 4 & 5
Youssef Soliman, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Amar J. Thosani, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist
Cristian Tomasetti, PhD	Consultant for ProgomiQ; Other financial/material interests (Royalties) in Exact Sciences.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
V. Liana Tsikitis, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
DeAnna M. Weaver, CNP, MSN	I do not have any relevant financial relationships with any ineligible companies.	None	2,4&5
Kun-Hsing Yu, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3 & 4
Alvin M. Zfass, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Panelist

The ACCME defines "relevant' financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
 The ACCME defines an "Ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients



♦ E-Syllabus ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

To ensure that you are receiving the most current slide sets presented, as well as keeping with City of Hope's "green initiative" to reduce waste, an e-syllabus containing slide sets is available for this activity online only **(printed presentation not available on-site)**. We recommend you access available presentations prior to the conference and bring your computer or mobile device fully charged. We gratefully acknowledge the presenters for their permission to offer this material as an e-syllabus.

E-Syllabus Download/Printing Instructions: (printed syllabus will not be provided on-site)

If you would like to download or print a copy of available presentations simply:

- 1) Visit the following link: 2025 AIGI | E-Syllabus: https://cme.cityofhope.org/content/2025-aigi-e-syllabus
- 2) Find the desired presentation and click on the title of the presentation you would like to download
- 3) The presentation will open and appear in PDF format
- 4) To save the presentation, click "Save As"
- 5) To print the presentation, click "Print"

AJCC Cancer Staging Forms

• Access to the AJCC Cancer Staging Forms is also available via the e-syllabus.

PLEASE NOTE:

- Some presentations not provided prior to the conference will be accessible post-activity.
- All presentations will be available for 4 weeks following the conclusion of this educational activity.
- Presentations have been uploaded at the discretion of each faculty member



WiFi Information

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

WiFi Network



Network:

Hilton Honors Meeting

Password:

CityofHopeAIGI2



♦ Meet the Faculty Reception ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

You're Invited!

Meet the Faculty Reception

Saturday, April 5, 2025



Waldorf Ballroom

Registered attendees are invited to attend the Meet the Faculty Reception.

Conference badge must be worn for admittance.



Upcoming Symposia

Upcoming Symposia

Scan QR codes for additional information



SAVE THE DATE

SAAS 10th Annual Meeting and Inaugural SAAS/LSS Joint Meeting

EMPOWERING CURRENT & FUTURE SURGICAL LEADERS

Hosted by K City of Hope.

September 4 to 5, 2025

The Waterfront Beach Resort, a Hilton Hotel Huntington Beach, California



Cityof Hope.



SAVE THE DATE



16TH Worldwide Congress

The Present and Future of Robotic Surgery

November 20 to 22, 2025

The Waterfront Beach Resort, a Hilton Hotel Huntington Beach, California, U.S.





Conference Schedule

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

SATURDAY, APRIL 5, 2025

- 7:00 7:50 AM BREAKFAST/REGISTRATION/EXHIBITS
- 7:50 8:00 AM Welcome & Announcements

8:00 – 9:55 AM **SESSION ONE:**

Unlocking the Secrets of Early Cancer Detection: Cutting-edge Strategies for the Next Frontier in Pancreaticobiliary Oncology Moderator: N. Jewel Samadder, MD, MS Revolutionizing GI Cancer Care Through AI Stephen B. Gruber, MD, PhD Decoding Cancer Signals: The High Stakes of AI Genomics and Liquid Biopsies Cristian Tomasetti, PhD Opportunities for Early Detection and Interception of GI/Pancreas Cancers Using Endoscopic Imaging Michelle A. Anderson, MD, MSc Beyond Boundaries: Bringing Advanced Cancer Detection to the World's Most Vulnerable Corners Jordan Iannuzzi, MD Panel Discussion

THE FOLLOWING 3 SESSIONS ARE NON-CME ACCREDITED.

9:55 – 10:05 AM REFRESHMENT BREAK/EXHIBITS

10:05 – 10:35 AM DEMONSTRATIONS NURSING/APP SUMMARY

Exhibit Hall	General Session
Demonstration by Histosonics Histotripsy: A New Platform in Human Health	
Time: 10:05 – 10:20 AM	Nursing/APP Summary
Demonstration by Medtronic	Time: 10:05 – 10:35 AM
The GI Genius™ Intelligent Endoscopy, Computer- aided Polyp Detection System Powered by AI	
Time: 10:20 – 10:35 AM	

10:35 – 10:40 AM

Transition to the General Session

Jonathan Kessler, MD Panel Discussion

10:40 AM – 12:15 PM SESSION TWO:

United Front: Multidisciplinary Strategies for Conquering Colorectal Liver Metastasis Moderator: Marwan Fakih, MD Revolutionizing Survival: Surgical Breakthroughs in Liver Directed Therapies

for Colorectal Cancer Gagandeep Singh, MD Should Liver Transplantation be a Standard Treatment Option for Metastatic Colorectal Cancer? Maarouf A. Hoteit, MD Pioneering Progress: Next-Gen Liver Directed Therapies Unveiled

THE FOLLOWING 5 SES	SSIONS ARE NON-CME ACCREDITED.	
12:15 – 12:30 PM	LUNCH/EXHIBITS	
12:30 – 1:15 PM	SATELLITE SYMPOSIUM by AstraZeneca Atrium Ballroom Key Considerations when Choosing a First-line Treatment Option for Unresectable Hepatocellular Carcinoma Jonathan Mizrahi, MD	
1:15 – 1:45 PM DEMONSTRATIONS NURSING/APP SUMMARY		
	Exhibit Hall	General Session
	Demonstration by Histosonics Histotripsy: A New Platform in Human Health Time: 1:15 – 1:30 PM	Numing (ADD Summore)
	Demonstration by Medtronic The GI Genius™ Intelligent Endoscopy, Computer- aided Polyp Detection System Powered by AI Time: 1:30 – 1:45 PM	Nursing/APP Summary Time: 1:15 – 1:45 PM
1:45 – 2:05 PM	PRODUCT THEATER by Amgen Atrium Ballroom FGFR2b Protein Overexpression: An Emerging IHC-based Biomarker in Gastric/ Gastroesophageal Junction Cancer Michelle K. Gleason, PhD, MS	
2:05 – 3:35 PM	SESSION THREE: Breaking Boundaries: Pioneering Advances in Rectal Cancer Management Moderator: Andreas M. Kaiser, MD Unleashing the Power of Immunotherapy: A New Dawn for Primary Colorectal Cancer Treatment Marwan Fakih, MD Precision Endoscopy: Transforming Colorectal Cancer Care from Diagnosis to Destruction Toufic Kachaamy, MD TNT and Organ Preservation: To Resect or Not to Resect? V. Liana Tsikitis, MD, MBA Panel Discussion	
3:35 PM	ADJOURN	
3:45 – 5:45 PM	MEET THE FACULTY RECEPTION	



♦ Conference Schedule ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

SUNDAY, APRIL 6, 2025

- 7:15 8:15 AM BREAKFAST/REGISTRATION/EXHIBITS
- 8:15 8:20 AM Welcome & Announcements

8:20 – 9:50 AM **SESSION FOUR:**

 Precision Paradigms: Redefining GI Cancer Management through Targeted Diagnostics and Therapies
 Moderator: Ajaz M. Khan, MD, MBA
 Maximizing Insights: Leveraging Artificial Intelligence to Extract Unseen Value from Pathology Slides in GI Cancer
 Kun-Hsing Yu, MD, PhD
 The Genetic Forecast: ctDNA's Role in Shaping the Present and Future of GI Cancer Treatment

Pashtoon Kasi, MD, MS

Precision Power: Advanced GI Cancer Treatment with Precision Radiotherapy Sameer Keole, MD

Panel Discussion

THE FOLLOWING 3 SESSIONS ARE NON-CME ACCREDITED.

9:50 – 10:00 AM	REFRESHMENT BREAK/EXHIBITS	
10:00 – 10:30 AM	DEMONSTRATIONS NURSING/APP SUMMARY	
	Exhibit Hall	General Session
	Demonstration by Pentax Medical	
	C2 CryoBalloon Ablation	
	Time: 10:00 – 10:15 AM	
	Demonstration by Mirai Medical	Nursing/APP Summary
	A New Era in GI Oncology: From Palliative Care	Time: 10:00 – 10:30 AM
	to Neoadjuvant Therapy, Transforming	
	Treatment with Pulsed Electric Fields	
	Time: 10:15 – 10:30 AM	
10:30 – 10:35 AM	Transitioning to the General Session	
10:35 AM– 12:00 PM	SESSION FIVE:	
	Next-Gen Dialogues in GI Oncology: Pioneering D	igital Frontiers and Equity
	Moderator: Vivek Kaul, MD	
	Revolutionizing Patient Interaction: AI's Role	in Transforming GI Oncology
	Communication	
	Hannah Farfour, DNP, AGPCNP-BC	
	Maximizing Impact: Harnessing the Full Poter	ntial of APPs in Multidisciplinary
	GI Oncology Teams	
	Sarah Enslin, PA-C	
	High-risk Patients and Health Disparities: Uni	resolved Issues in Multi-Cancer
	Early Detection Screening	
	Gregory Idos, MD, MS	

THE FOLLOWING 5 SES	SIONS ARE NON-CME ACCREDITED.	
12:00 – 12:15 PM	LUNCH/EXHIBITS	
12:15 – 12:35 PM	PRODUCT THEATER by Steris Atrium Ballroom Liquid Nitrogen for Treatment of Esophageal Cancer - HOW COOL IS THAT? Michael S. Smith, MD, MBA	
12:40 – 1:00 PM	PRODUCT THEATER by Guardant Health Atrium Ballroom Methylation Based ctDNA Analysis for the Detection of Molecular Residual Disease (MRD) in Stage II+ CRC Brandon Guida, PhD, MS	
1:00 – 1:30 PM	DEMONSTRATIONS NURSING/APP SUMMARY	
	Exhibit Hall	General Session
	Demonstration by Pentax MedicalC2 CryoBalloon AblationTime: 1:00 – 1:15 PMDemonstration by Mirai MedicalA New Era in Gl Oncology: From Palliative Careto Neoadjuvant Therapy, TransformingTreatment with Pulsed Electric FieldsTime: 1:15 – 1:30 PM	Nursing/APP Summary Time: 1:00 – 1:30 PM
1:30 – 3:25 PM	 SESSION SIX: Collaborative Precision: Organ Preservation Next Frontier Moderator: Pashtoon Kasi, MD, MS Organ Preservation Options after TNT and Near-complete Response in Rectal Cancer Emre Gorgun, MD, MBA Organ Preservation for Esophageal Cancer: Are There Options? Steven H. Lin, MD, PhD The Role of the Endoscopist in Esophageal Organ Preservation Michael S. Smith, MD, MBA Endoscopist as Surgeon: Expanding Boundaries of Interventional Endoscopy Neil R. Sharma, MD Panel Discussion 	
3:25 PM	CONFERENCE ADJOURNS	

City of Hope may find it necessary to substitute faculty with comparable expertise on those rare occasions necessitated by illness, unforeseen scheduling conflicts or extraordinary occurrences.



♦ Conference Information ♦

Annual Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care

TASKS:

Conference Evaluation opens April 6, 2025 at 3:25 PM: https://cme.cityofhope.org/node/15132/course-object/36778

Conference Feedback opens April 6, 2025 at 3:25 PM: https://cme.cityofhope.org/node/15132/course-object/36779

IMPORTANT:

Last day to complete Conference Tasks is Friday, April 11, 2025

You can scan the QR Code below to complete the tasks on your mobile device once the conference adjourns, starting on 04/06/25 at 3:25 PM



For assistance, contact the Department of Continuing Medical Education at 626-218-5622 or <u>cme@coh.org</u>.



Acknowledgment of Exhibit Support

City of Hope[®] gratefully acknowledges the generous support from:

AMGEN ASTRAZENECA BAYER ONCOLOGY BEIGENE CARIS LIFE SCIENCES CASTLE BIOSCIENCES CIRCULOGENE COHERUS COOK MEDICAL DIGESTIVE CARE INC. GUARDANT HEALTH HISTOSONICS IPSEN BIOPHARMACEUTICALS JAZZ PHARMACEUTICALS INC. NATERA INC. NOVARTIS OLYMPUS OVESCO ENDOSCOPY PFIZER ONCOLOGY STERIS TAEWOONG MEDICAL USA TAIHO ONCOLOGY INC. TAKEDA TERSERA THERAPEUTICS

Exhibit Support as of March 20, 2025



Sponsorship Acknowledgment

City of Hope[®] gratefully acknowledges the generous sponsorship from:

DIAMOND SPONSOR ASTRAZENECA

PLATINUM SPONSORS AMGEN GUARDANT HEALTH STERIS



Sponsorship Acknowledgment

City of Hope[®] gratefully acknowledges the generous sponsorship from:

DEMONSTRATIONS BY HISTOSONICS MEDTRONIC



Sponsorship Acknowledgment

City of Hope[®] gratefully acknowledges the generous sponsorship from:

DEMONSTRATIONS BY MIRAI MEDICAL PENTAX MEDICAL

Liquid Nitrogen For Treatment of Esophageal Cancer - HOW COOL IS THAT?

SUNDAY, APRIL 6th 12:15 - 12:35PM

Learn about the role of Liquid Nitrogen Spray Cryotherapy (LNSCT) and supporting clinical data in treating esophageal cancer


The presentation will focus on utilizing cryotherapy in the following clinical scenarios:

- Salvage for incomplete or non-respondent
- Recurrence post-definitive therapy
- Non-surgical on concurrent systemic therapy
- Strictures resulting from radiation



Michael S. Smith, MD, MBA Associate System Chief of Gastroenterology Mount Sinai Health System Associate Professor of Medicine Icahn School of Medicine at Mount Sinai

Liquid Nitrogen Spray Cryotherapy Application to GE Junction Tumor







steris.com/trufreeze


© 2025 STERS All Rights Reserved. 762260 Rev. A

ASCO & ESMO TREATMENT GUIDELINES FOR METASTATIC COLORECTAL CANCER

Based on Phase 3, randomized, open-label, multicenter study in Japanese patients evidence PARADIGM study, tumor sidedness is now included in major medical associations' treatment protocols.^{1,2,3}

About 70% of CRC tumors are on the left—and not all treatments are recommended for both sides.⁴

ASCO Guideline: Anti–EGFR therapy plus doublet chemotherapy 1L for patients with WT RAS* left-sided mCRC Strength of recommendation: Strong^{2,5}



Cf = chemotherapy; dMMR = deficient mismatch repair; Doublet Cf = FOLFOX; CAPOX or FOLFOR; MOT = multiblicipleary team; MDI = microsatellite instability; MDS = microsatellite adults; Triplet Cf = FOLFORR. This signifies is derived from recommendations in *Deatment of Metastatic Colorvatal Cancer*. ASCO Guideline, Tries is a tool based on an ASCO Guideline and is not intended to autotitute for dependent professional judgment of the

This algorithm is derived from recommendations in Neutrient of Metastate Colorestal Cancer. ACCO Galatime, This is a four based on an ACCO Galatime and is not intereded to additude to the independent protessional galgerent of the treating physician. Practice galatimes do not account for individual variation among palaents. This tool does not purport to suggest any particular course of medical treatment. Use of the galatime and this tool are voluntary.

"Defined as wild type in both K/RAS and N/RAS

11. = first-line, ADD3 = American Society of Clinical Decology, EEFR = epidemial growth factor receptor, ESM0 = European Society for Medical Decology, er/SHC = metastatic colonectal cancer, 05 = overall servicel VEOF = stacular entitchilal growth factor; WT = wild type.

ESMO now emphasizes that primary tumor location may be prognostic and predictive for patient outcomes³

Doublet chemotherapy plus an anti-EGFR mAb is the preferred 1L option for patients with WT RAS^{*} and WT BRAF left-sided mCRC³




Figure 2. Management of stage IV unresectable mCRC in first-line therapy.

5-FU, 5-Bustourusi: Ch7, chemotherapy, dMMR, deficient mixmatch repair; EGFR, epidermal growth factor receptor; ENA, European Medicines Agency; ESCAT, ESMO Scale for Clinical Actionability of Molecular Targets; EDA, Food and Drug Administration; FOLFRL, losscoverin-5-fluorescul-instaces; FOLFOX, losscoverin-5-fluorescular Targets; EDA, Food and Drug Administration; FOLFRL, losscoverin-5-fluorescul-instaces; FOLFOX, losscoverin-5-fluorescular Targets; EDA, ESRO-Magnitude of Clinical Banefit Scale; mCRC, matantatic colorectal cancer; MSI-H, microsofelite instability-high; mut, matant; PO, prograssion diseas; FS, performance status; 5-L Sogdur-gimeraci-desect; vit, wild-scale; mCRC, matantatic colorectal cancer; MSI-H, microsofelite instability-high; mut, matant;

In patients presenting with cardiotoxicity and/or hand-foot syndrome on S-FU or capacitabine-based Ch7, S-I may be used as an alternative D181.

Additional details on treatments and drug combinations can be found under the section 'Management of advanced and metastatic disease without potential conversion' (subsections First-line treatment' and 'Second-line treatment').

In Inal or elderly patients unable to tolerate ChT whose tumours are left-sided and RAS-et.

FOUR REceturinals ESMO-MCBS vt1 score: 4, FOUROX4-panhamanals ESMO-MCBS vt1 score: 4, mFOUROR6-panhamanals ESMO-MCBS vt1 score: 3,**

VOLFOX4-panitumumab ESMO-MCBS vt1 score: 4; modified FOLFOX6-panitumumab ESMO-MCBS vt1 score: 3; for FOLFRi-ceturimab ESMO-MCBS vt1 score: 4;"

"In a very selected population.

"CAPOX- or FOLFOX4-besacizumab ESMO-MCBS +13 score 1."

"A triplet with FOLFOXIRI plus bevacizumab is an option for selected patients with good PS and without comorbidities (LB, ESMO-MCBS +11 score; 2)."

"ESNO-MCBS vLP was used to calculate scores for therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESNO-MCBS Working Group and validated by the ESNO Guidelines Committee (https://www.esmo.org/publelines/como-mcbs/esno-mcbs-realuation-forms).

"ESCAT scores apply to genomic attentions only. These scores have been defined by the guideline authors and salidated by the ESMO Translational Research and Precision Medicine Working Group." See Supplementary Table SI, available at https://doi.org/10.1018/j.annorc.2022.00.003, for more information on ESCAT scores.

Defined as wild type in both KRAS and NRAS

• first-line; EEPR = epidemnal growth tactor receptor; EEMD = European Society for Medical Oncology, mAb = menodional antibody. mORC = metastatic colorectal caricar; WT = wild type.

Yeshino T, Watanabe J, Shitara K, et al. Presented at American Society of Clinical Oncology Annual Meeting: June 3-7, 2022. Discapp. Binais. USA. 2. Monix V, Kennedy E, Banter N, et al. J Clin Oncol. 2022. 1-23.
 Cervantes A, Adam P, Rosello S, et al. Ann Oncol. 2023;34:10-32. 4. Banan B, Daupek N, Tellik N, et al. Gastroentente Res. 2018;11:264-273. 5. Systemic therapy for metablatic colonectal cancer (mCRC) algorithm. ASCO Bantelmeetin. 2022.

© 2023 Amgen Inc. All rights reserved. USA-954-80406 4/2

